Data Readout

Satellos moves BASECAMP DMD readout timeline as trial keeps enrolling

Satellos pushed its Phase 2 BASECAMP completion date back a year to March 2027, yet still guides to Q4 2026 top-line data testing SAT-3247's muscle-strength effect in ambulatory boys with Duchenne.

By AppliedXLJuly 13, 2026Trial NCT07287189

Executive Summary

Satellos Bioscience is running the first placebo-controlled human trial of SAT-3247, its oral candidate for Duchenne muscular dystrophy, in ambulatory boys, with top-line data guided for the fourth quarter of 2026.
The trial's registered completion date moved out by a year even as recruiting continued and enrollment held at target, a pattern that reads as routine trial administration rather than a sign of trouble.
Earlier open-label data in adults showed strength gains sustained or improved over roughly a year of treatment, giving the sponsor a rationale to advance into a randomized pediatric design, though that adult signal cannot stand in for a placebo-controlled result.
No other industry trial targets this same mechanism in Duchenne muscular dystrophy, so the readout will land without a direct precedent to benchmark against, only broader small-molecule and gene-therapy programs pursuing different biology in the same disease.

The trial

BASECAMP (NCT07287189) is a randomized, placebo-controlled Phase 2 study enrolling 51 ambulatory boys aged 7 to under 10 with Duchenne muscular dystrophy across sites in the United States, Canada, the United Kingdom, Spain, Belgium, Poland, Serbia and Australia. The trial tests SAT-3247's effect on muscle strength, safety and tolerability over three months of dosing, with muscle function, quality and regeneration as secondary measures. Satellos dosed its first participant on Feb. 12, 2026, after clearing FDA and other regulatory reviews, and has guided to enrollment completion in the third quarter of 2026 with top-line data in the fourth quarter. NCT07287189+1

Probability of Success

Endpoint Met24%

Completes67%

Clinical Significance20%

Regulatory24%

The timing shift

The trial's primary completion date moved from March 31, 2026 to March 31, 2027, a 12-month change logged in the registry on Dec. 19, 2025, shortly after the study was first posted. The trial's status also cycled from Active, not recruiting back to Recruiting on Jan. 5, 2026. Enrollment held flat at its target of 51 patients across that period, a routine hold rather than a cut. Satellos' own guidance, issued March 27, 2026, still points to top-line data in the fourth quarter of 2026, a window that ends roughly 15 months before the registry's current primary completion date. NCT07287189+1

Prior signal

SAT-3247 is an oral small molecule designed to restore muscle regeneration by correcting deficits in muscle stem cell polarity. In TRAILHEAD, a follow-on open-label study, four adults who originally took part in a 28-day Phase 1b trial were re-dosed and showed grip strength improvements that were maintained or improved over an aggregate of 9 to 13 months of exposure, alongside reductions in muscle-degeneration biomarkers measured by proteomics. CEO Frank Gleeson said continued data from TRAILHEAD, where the company observed greater improvements in participants with higher baseline muscle mass, "has increased our confidence as we advance BASECAMP". That evidence comes from an open-label design without a placebo arm, so it cannot establish what a controlled comparison will show in the pediatric population BASECAMP is testing. Satellos

Competitive frame

SAT-3247 targets AAK1, and no other industry trial in Duchenne muscular dystrophy is built around that target, leaving BASECAMP without a direct mechanistic comparator. The broader Duchenne field is active across other mechanisms: Sarepta's gene therapy delandistrogene moxeparvovec, Dyne Therapeutics' oligonucleotide zeleciment rostudirsen, and Italfarmaco's HDAC inhibitor givinostat are each in later-stage testing in the same indication, but none shares SAT-3247's target or its small-molecule regeneration mechanism. That isolation means BASECAMP's result will be judged largely on its own terms rather than against a same-mechanism track record.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.